close
Add to watchlist
Supergen Inc (SUPG) Healthcare, Biotechnology & Drugs
SuperGen, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of therapies to treat patients with cancer. The company licensed its new drug application approved product, Dacogen for the treatment of patients with myelodysplastic syndromes. It primarily focuses on developing MP-470, a DNA repair suppressor; SGI-1776, a PIM kinase inhibitor; MP-529, an Aurora kinase inhibitor; SGI-110, a DNMT1 inhibitor; and SGI-1252, a JAK2 inhibitor. SuperGen also has an approved product, Mitozytrex for the treatment of solid tumors. In addition, the company is developing Orathecin, a Phase III clinical trial product for the treatment of solid tumors; Partaject busulfan, a Phase I/II clinical trial product for neoplastic meningitis/bone marrow transplant; Partaject Orathecin, a non-clinical stage product for the treatment of solid tumors; and CZ 112, a Phase I clinical trial product for the treatment of solid tumors. It is also developing Cremophor-free paclitaxel, a non-clinical stage product for the treatment of solid tumors; Avicine, a therapeutic vaccine for the treatment of cancer, which is in Phase II trial; VEGF, a non-clinical stage product for the treatment of anti-angiogenesis; PZG, a Phase II clinical trial product for the treatment of type II diabetes; and AM454, a phosphocholine derivative, which is in non-clinical stage for obesity/diabetes. The company sells its products to clinics, hospitals, hospital buying groups, drug distributors, and wholesalers in the United States and Europe. SuperGen was founded in 1991 and is based in Dublin, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 2.15 |
| Volume | 0 |
| Volume Avg | 450018 |
| 52 Week High | 3.35 |
| 52 Week Low | 1.99 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | 0.00 |
| EPS change Q/Q | -18.18% |
| EPS change Q/Q Yr ago | 12.5% |
| EPS change Q/Q next Q est | -100% |
| EPS change Y/Y | -67.86% |
| REV change Q/Q | 11.76% |
| REV change Q/Q Yr ago | 18.75% |
| EPS next Q est | 0.00 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |